PATENT CLAIM ANALYSIS

Application Number: 15972966
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "230500"]

Abstract:
Chemical entities of Formula (I): Including enantiomers thereof, wherein R 1  has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

Claim (Index 17):
A method of treating a depressive disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, of Formula (I): wherein: R 1  is \u2014H; or R 1  is \u2014C 1-6 alkyl, optionally substituted with one or more members, each independently selected from the group consisting of: -halo, -hydroxy, -alkoxy, -amino and -carboxyl; or R 1  is \u2014C 3-8 alkenyl or \u2014C 3-8 alkynyl, each optionally substituted with one or more members, each independently selected from the group consisting of: -halo, -hydroxy, \u2014C 1-4  alkyl, \u2014C 1-4 alkoxy, and amino; or R 1  is \u2014(CH 2 ) n aryl, \u2014(CH 2 ) n heteroaryl, \u2014(CH 2 ) n cycloalkyl, or \u2014(CH 2 ) n heterocycloalkyl, each optionally substituted with one or more members, each independently selected from the group consisting of: -halo, -hydroxy, \u2014C 1-4  alkyl, \u2014C 1-4 alkoxy, and -amino, wherein n is independently an integer selected from 0, 1, 2, 3, and 4; or R 1  is \u2014COR 2 , \u2014CONR 3 R 4 , \u2014CR 5 R 6 NR 7 R 8 , \u2014CHR 9 R 10 , or \u2014C(OH)R 11 R 12 , wherein R 2 , R 3 , R 4 , R 7  and R 8  are each independently selected from the group consisting of: \u2014H, \u2014C 1-8 alkyl, and \u2014C 1-8 haloalkyl; R 5  and R 6  are each independently selected from the group consisting of: \u2014H, -halo, \u2014NH 2 , \u2014C 1-8 alkyl, \u2014C 1-8 haloalkyl, \u2014(CH 2 ) n CONH 2 , \u2014(CH 2 ) n COOH, \u2014(CH 2 ) n aryl, \u2014(CH 2 ) n heteroaryl, \u2014(CH 2 ) n cycloalkyl, and \u2014(CH 2 ) n heterocycloalkyl, each optionally substituted with one or more members, each independently selected from the group consisting of: -guanidyl, -urea, -halo, -alkyl, -hydroxy, -amino, -alkoxy, -2,3-dihydro-1H-pyrrole-1-carboxamide, \u2014(CH 2 ) n CONR 1A R 1B , \u2014(CH 2 ) n NHC(\u2550O)R 1A , \u2014(CH 2 ) n NR 1A R 1B , \u2014(CH 2 ) n OR 1C , \u2014(CH 2 ) n SR 1C  and \u2014(CH 2 ) n SeR 1C , wherein n is independently an integer selected from 0, 1, 2, 3, and 4; each R 1A  is independently selected from the group consisting of: \u2014H, \u2014C 1-8 alkyl, \u2014(CH 2 ) n CONH 2 , and \u2014(CH 2 ) n heterocycloalkyl, wherein n is independently an integer selected from 0, 1, 2, 3, and 4; each R 1B  is independently selected from the group consisting of: \u2014H, \u2014C 1-8 alkyl, and \u2014(CH 2 ) n CONH 2 , wherein n is independently an integer selected from 0, 1, 2, 3, and 4; each R 1C  is independently selected from the group consisting of: \u2014H, \u2014C 1-8 alkyl, \u2014C 1-8 haloalkyl, \u2014(CH 2 ) n CONH 2 , \u2014(CH 2 ) n COOH, \u2014(CH 2 ) n aryl, \u2014(CH 2 ) n heteroaryl, \u2014(CH 2 ) n cycloalkyl, and \u2014(CH 2 ) n heterocycloalkyl, wherein n is independently an integer selected from 0, 1, 2, 3, and 4; R 9  and R 10  are each independently selected from the group consisting of: \u2014H, \u2014C 1-8 alkyl, and \u2014C 1-8 haloalkyl, said alkyl optionally substituted with up to 3 members, each independently selected from the group consisting of: -amino, -hydroxy and -carboxyl; or optionally R 9  and R 10  taken together with the carbon to which they are attached form an optionally substituted five membered heteroaryl or heterocycloalkyl ring; and R 11  and R 12  are independently selected from the group consisting of: \u2014H, \u2014C 1-6 alkyl, and \u2014C 1-6 haloalkyl, said \u2014C 1-6 alkyl, and \u2014C 1-6 haloalkyl optionally substituted with up to 3 members, each independently selected from the group consisting of: -hydroxy and amino; or pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 93.0
- Lexical Diversity: 1.38636
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15253645', '14279716', '14991786', '14445498', '14199844']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7291132827051873
- 35 USC 102 Novelty (BERT): 0.5525573110326449
- Combined Prediction Score: 0.7114576855379331
- Mean Citation Score: 292.5404000000001
- Max Citation Score: 398.32794
- Similarity Product: 354.23070582432746

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test